Skip to main content
. 2015 Feb 3;5:8198. doi: 10.1038/srep08198

Figure 1. Effect of PAR-1, GPVI and α2β1 inhibitors on thrombin- and collagen-induced platelet aggregation.

Figure 1

(A) Representative platelet aggregation profiles following platelet activation with 0.75 U/mL Thrombin (shown in blue) or 30 μg/mL collagen (shown in black). (B) Effect of PAR-1 inhibition on thrombin-induced platelet aggregation, and of GPVI and α2β1 inhibition on collagen-induced platelet aggregation. Washed human platelets were pre-incubated with the inhibitors for 5 min, then 0.75 U/mL thrombin or 30 μg/mL collagen were added to trigger platelet aggregation. Results are presented as mean ± SE (n = 4–6). *p<0.05 (Mann-Whitney test). Coll: collagen; Thr: thrombin; Fab-OM2: Fab fragment of the anti-GPVI monoclonal antibody OM2; BTT: BTT 3033; SCH: SCH 79797.